Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -1456.00%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-1456.00%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$4.12M
EBITDA Margin
-38402.78%
TTM Avg
-17909.83%
3Y Avg
-9620.57%
5Y Avg
-7243.11%
Market Cap
$4.15M
EBITDA Margin
-763.39%
TTM Avg
-1175.93%
3Y Avg
-1273.50%
5Y Avg
-867.10%
Market Cap
$4.02M
EBITDA Margin
-890.82%
TTM Avg
-527.81%
3Y Avg
-554.45%
5Y Avg
-445.87%
Market Cap
$4.23M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
Market Cap
$4.34M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$3.79M
EBITDA Margin
-334.54%
TTM Avg
-323.48%
3Y Avg
-700.81%
5Y Avg
-1335.84%
Market Cap
$3.63M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$3.58M
EBITDA Margin
-2774.55%
TTM Avg
-3680.87%
3Y Avg
-3159.91%
5Y Avg
-3026.36%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.09M | -1456.00% | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.12M | -38402.78% | -17909.83% | -9620.57% | -7243.11% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.15M | -763.39% | -1175.93% | -1273.50% | -867.10% |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.02M | -890.82% | -527.81% | -554.45% | -445.87% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.23M | -159.06% | -237.19% | -222.87% | -159.05% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| Evogene Ltd. (EVGN)vs › | $3.79M | -334.54% | -323.48% | -700.81% | -1335.84% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.63M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| Nexalin Technology, Inc. (NXL)vs › | $3.58M | -2774.55% | -3680.87% | -3159.91% | -3026.36% |
| Eocene Ltd. (EOCN)vs › | $3.57M | N/A | N/A | N/A | N/A |
Gross Margin
N/A
EBITDA Margin
-1456.0%
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-03-31 | -1160.00% |
